, 23 Baylor Institute for Immunology Research, Brooke Army Medical Center

, 27 Division of Immunology and Rheumatology, 26 Adaptive Biotechnologies, p.28

I. Atreca, R. City, C. A. , and U. , 29 Cellular & Molecular Pathology Graduate Program

, 32 Immunology Program, Memorial Sloan-Kettering Cancer Center, Institut GrustaveRoussy, vol.33, p.34

F. S. Hodi, O. Day, S. J. Mcdermott, D. F. Weber, R. W. Sosman et al., Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, vol.363, issue.8, pp.711-734, 2010.

J. Galon, A. Costes, F. Sanchez-cabo, A. Kirilovsky, B. Mlecnik et al., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, vol.313, issue.5795, pp.1960-1964, 2006.

B. Mlecnik, M. Tosolini, A. Kirilovsky, A. Berger, G. Bindea et al., Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction, J Clin Oncol Off J Am Soc Clin Oncol, vol.29, issue.6, pp.610-618, 2011.

E. K. Broussard and M. L. Disis, TNM staging in colorectal cancer: T is for T cell and M is for memory, J Clin Oncol Off J Am Soc Clin Oncol, vol.29, issue.6, pp.601-604, 2011.

W. H. Fridman, F. Pages, C. Sautes-fridman, and J. Galon, The immune contexture in human tumours: impact on clinical outcome, Nat Rev Cancer, vol.12, issue.4, pp.298-306, 2012.

J. Galon, F. Pages, F. M. Marincola, H. K. Angell, M. Thurin et al., Cancer classification using the Immunoscore: a worldwide task force, J Transl Med, vol.10, p.205, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00780742

J. Galon, B. Mlecnik, G. Bindea, H. K. Angell, A. Berger et al., Towards the introduction of the 'Immunoscore' in the classification of malignant tumours, J Pathol, vol.232, issue.2, pp.199-209, 2014.

D. G. Denardo, D. J. Brennan, E. Rexhepaj, B. Ruffell, S. L. Shiao et al., Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy, Cancer Discovery, vol.1, issue.1, pp.54-67, 2011.

P. A. Ascierto, M. Capone, W. J. Urba, C. B. Bifulco, G. Botti et al., The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment, J Transl Med, vol.11, p.54, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00804641

B. A. Fox, D. J. Schendel, L. H. Butterfield, S. Aamdal, J. P. Allison et al., Defining the critical hurdles in cancer immunotherapy, J Transl Med, vol.9, p.214, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00691923

D. R. Green, T. Ferguson, L. Zitvogel, and G. Kroemer, Immunogenic and tolerogenic cell death, Nature Reviews Immunol, vol.9, issue.5, pp.353-63, 2009.
DOI : 10.1038/nri2545

URL : http://europepmc.org/articles/pmc2818721?pdf=render

L. Zitvogel, N. Casares, M. O. Pequignot, N. Chaput, M. L. Albert et al., Immune response against dying tumor cells, Adv Immunol, vol.84, pp.131-79, 2004.
DOI : 10.1016/s0065-2776(04)84004-5

URL : https://hal.archives-ouvertes.fr/pasteur-01402386

L. Zitvogel, O. Kepp, and G. Kroemer, Immune parameters affecting the efficacy of chemotherapeutic regimens, Nat Rev Clin Oncol, vol.8, issue.3, pp.151-60, 2011.

N. Casares, M. O. Pequignot, A. Tesniere, F. Ghiringhelli, S. Roux et al., Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death, J Exp Med, vol.202, issue.12, pp.1691-701, 2005.

L. Menger, E. Vacchelli, S. Adjemian, I. Martins, Y. Ma et al., Cardiac glycosides exert anticancer effects by inducing immunogenic cell death, Sci Transl Med, vol.4, issue.143, pp.143-99, 2012.

, FDA: (US) Food and Drug Administration; Foxp3: forkhead box P3

, GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GLP: Good Laboratory Practice; GM-CSF: granulocyte-macrophage colony-stimulating factor

, HLA: human leukocyte antigen; HMGB1: high mobility group box 1

, ICD: immunogenic cell death; ICH: International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

, ICR: immunologic constant of rejection, vol.2, p.3

, IEC: International Electrotechnical Commission; IFN-?:interferon gamma

, IL-6: interleukin 6; ILC: innate lymphoid cells; irAE: immune-related adverse event; IRC?: Immune Repertoire Capture?; ISO: International Organization for Standardization; ISV: in situ vaccination; ITA: immune-targeted agent; KIR: killercell immunoglobulin-like receptor

, MICA: major histocompatibility complex class I-related chain A; MICB: major histocompatibility complex class Irelated chain B; mRNA: messenger RNA; MTD: maximum tolerated dose, MHC: major histocompatibility complex; MIBBI: Minimum Information for Biological and Biomedical Investigations

, NK: natural killer; PBMC: peripheral blood mononuclear cells; PCR: polymerase chain reaction; PD: pharmacodynamics; PD-1: programmed cell death protein 1

P. , of PD-1; PK: pharmacokinetics; qPCR: quantitative polymerase chain reaction; RNAseq: sequencing technology to sequence the repertoire of RNA transcripts in a biologic sample; RUO: research use only; sMICA: soluble major histocompatibility complex class I-related chain A; sMICB: soluble major histocompatibility complex class I

, TDLN: tumor-draining lymph node; TIL: tumor-infiltrating lymphocyte; TLR7: tolllike receptor 7; TLR9: toll-like receptor 9

, TNM: tumor-node-metastasis (staging)

, Treg: regulatory T cell

, TSDR: Treg cell-specific demethylated region

T. Panaretakis, O. Kepp, U. Brockmeier, A. Tesniere, A. C. Bjorklund et al., Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death, EMBO J, vol.28, issue.5, pp.578-90, 2009.

Y. Ma, L. Aymeric, C. Locher, S. R. Mattarollo, N. F. Delahaye et al., Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy, J Exp Med, vol.208, issue.3, pp.491-503, 2011.
URL : https://hal.archives-ouvertes.fr/pasteur-00576679

F. Ghiringhelli, L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma et al., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1betadependent adaptive immunity against tumors, Nature Med, vol.15, issue.10, pp.1170-1178, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00419823

M. L. Albert, B. Sauter, and N. Bhardwaj, Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs, Nature, vol.392, issue.6671, pp.86-95, 1998.

C. B. Thompson, Apoptosis in the pathogenesis and treatment of disease, Science, vol.267, issue.5203, pp.1456-62, 1995.

M. Michaud, I. Martins, A. Q. Sukkurwala, S. Adjemian, Y. Ma et al., Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice, Science, vol.334, issue.6062, pp.1573-1580, 2011.

A. Tesniere, F. Schlemmer, V. Boige, O. Kepp, I. Martins et al., Immunogenic death of colon cancer cells treated with oxaliplatin, Oncogene, vol.29, issue.4, pp.482-91, 2010.

L. Senovilla, L. Galluzzi, G. Marino, I. Vitale, M. Castedo et al., Immunosurveillance against cancer-associated hyperploidy, Oncotarget, vol.3, issue.11, pp.1270-1271, 2012.

T. Yamazaki, D. Hannani, V. Poirier-colame, S. Ladoire, C. Locher et al., Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists, Cell Death Differ, vol.21, issue.1, pp.69-78, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02047406

S. Ladoire, K. Chaba, I. Martins, A. Q. Sukkurwala, S. Adjemian et al., Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens, Autophagy, vol.8, issue.8, pp.1175-84, 2012.

E. B. Golden, D. Frances, I. Pellicciotta, S. Demaria, H. Barcellos-hoff et al., Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death, Oncoimmunol, vol.3, 2014.
DOI : 10.4161/onci.28518

URL : https://www.tandfonline.com/doi/pdf/10.4161/onci.28518?needAccess=true

M. A. Postow, M. K. Callahan, C. A. Barker, Y. Yamada, J. Yuan et al., Immunologic correlates of the abscopal effect in a patient with melanoma, N Engl J Med, vol.366, issue.10, pp.925-956, 2012.

S. C. Formenti and S. Demaria, Combining radiotherapy and cancer immunotherapy: a paradigm shift, J Natl Cancer Inst, vol.105, issue.4, pp.256-65, 2013.
DOI : 10.1093/jnci/djs629

URL : http://europepmc.org/articles/pmc3576324?pdf=render

J. L. Gulley, P. M. Arlen, A. Bastian, S. Morin, J. Marte et al., Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer, Clin Cancer Res, vol.11, issue.9, pp.3353-62, 2005.

E. Wang, A. Worschech, and F. M. Marincola, The immunologic constant of rejection, Trends in Immunol, vol.29, issue.6, pp.256-62, 2008.
URL : https://hal.archives-ouvertes.fr/hal-02143596

E. B. Golden, S. Demaria, P. B. Schiff, A. Chachoua, and S. C. Formenti, An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer, Cancer Immunol Res, vol.1, issue.6, pp.365-72, 2013.

M. G. Ruocco, K. A. Pilones, N. Kawashima, M. Cammer, J. Huang et al., Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects, J Clin Invest, vol.122, issue.10, 2012.
DOI : 10.1172/jci61931

URL : http://www.jci.org/articles/view/61931/files/pdf

V. Groh, J. Wu, C. Yee, and T. Spies, Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation, Nature, vol.419, issue.6908, pp.734-742, 2002.
DOI : 10.1038/nature01112

M. Jinushi, F. S. Hodi, and G. Dranoff, Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity, Proc Natl Acad Sci, vol.103, issue.24, pp.9190-9195, 2006.

S. Gasser, S. Orsulic, E. J. Brown, and D. H. Raulet, The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor, Nature, vol.436, issue.7054, pp.1186-90, 2005.

M. Kalos and C. H. June, Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology, Immunity, vol.39, issue.1, pp.49-60, 2013.

J. J. Melenhorst and B. L. Levine, Innovation and opportunity for chimeric antigen receptor targeted T cells, Cytotherapy, vol.15, issue.9, pp.1046-53, 2013.
DOI : 10.1016/j.jcyt.2013.02.007

M. Ruella and M. Kalos, Adoptive immunotherapy for cancer, Immunol Rev, vol.257, issue.1, pp.14-38, 2014.

M. Kalos, B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp et al., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, vol.3, issue.95, pp.95-73, 2011.
DOI : 10.1126/scitranslmed.3002842

URL : http://stm.sciencemag.org/content/3/95/95ra73.full.pdf

D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, and C. H. June, Chimeric antigen receptormodified T cells in chronic lymphoid leukemia, N Engl J Med, vol.365, issue.8, pp.725-758, 2011.
DOI : 10.1056/nejmoa1103849

URL : http://europepmc.org/articles/pmc3387277?pdf=render

S. A. Grupp, M. Kalos, D. Barrett, R. Aplenc, D. L. Porter et al., Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, vol.368, issue.16, pp.1509-1527, 2013.
DOI : 10.1056/nejmoa1215134

URL : http://europepmc.org/articles/pmc4058440?pdf=render

M. Kalos, Biomarkers in T cell therapy clinical trials, J Transl Med, vol.9, p.138, 2011.

G. L. Beatty, A. R. Haas, M. V. Maus, D. A. Torigian, M. C. Soulen et al., Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies, Cancer Immunol Res, vol.2, issue.2, pp.112-132, 2014.

M. L. Davila, I. Riviere, X. Wang, S. Bartido, J. Park et al., Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, vol.6, issue.224, pp.224-249, 2014.

M. A. Caligiuri, Human natural killer cells, Blood, vol.112, issue.3, pp.461-470, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00431858

E. Vivier, D. H. Raulet, A. Moretta, M. A. Caligiuri, L. Zitvogel et al., Innate or adaptive immunity? The example of natural killer cells, Science, vol.331, issue.6013, pp.44-53, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00611585

E. Vivier, S. Ugolini, D. Blaise, C. Chabannon, and L. Brossay, Targeting natural killer cells and natural killer T cells in cancer, Nat Rev Immunol, vol.12, issue.4, pp.239-52, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00685473

J. S. Miller, Y. Soignier, A. Panoskaltsis-mortari, S. A. Mcnearney, G. H. Yun et al., Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer, Blood, vol.105, issue.8, pp.3051-3058, 2005.

M. A. Geller, S. Cooley, P. L. Judson, R. Ghebre, L. F. Carson et al., A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer, Cytotherapy, vol.13, issue.1, pp.98-107, 2011.

V. Bachanova, L. J. Burns, D. H. Mckenna, J. Curtsinger, A. Panoskaltsis-mortari et al., Allogeneic natural killer cells for refractory lymphoma, Cancer Immunol Immunother, vol.59, issue.11, pp.1739-1783, 2010.

A. Wiernik, B. Foley, B. Zhang, M. R. Verneris, E. Warlick et al., Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition, Clin Cancer Res, vol.19, issue.14, pp.3844-55, 2013.

M. K. Gleason, J. A. Ross, E. D. Warlick, T. C. Lund, M. R. Verneris et al., CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets, Blood, vol.123, pp.3016-3042, 2014.

G. Cartron, L. Dacheux, G. Salles, P. Solal-celigny, P. Bardos et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene, Blood, vol.99, issue.3, pp.754-762, 2002.

D. Cornec, A. Tempescul, S. Querellou, P. Hutin, J. O. Pers et al., Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy, Ann Hematol, vol.91, issue.5, pp.715-736, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00771121

S. P. Treon, M. Hansen, A. R. Branagan, S. Verselis, C. Emmanouilides et al., Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.3, pp.474-81, 2005.

W. K. Weng and R. Levy, Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma, J Clin Oncol Off J Am Soc Clin Oncol, vol.21, issue.21, pp.3940-3947, 2003.

A. Musolino, N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti et al., Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.26, issue.11, pp.1789-96, 2008.

K. Tamura, C. Shimizu, T. Hojo, S. Akashi-tanaka, T. Kinoshita et al., FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer, Ann Oncol, vol.22, issue.6, pp.1302-1309, 2011.

F. Bibeau, E. Lopez-crapez, D. Fiore, F. Thezenas, S. Ychou et al., Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, issue.7, pp.1122-1131, 2009.

S. P. Hilchey, O. Hyrien, T. R. Mosmann, A. M. Livingstone, J. W. Friedberg et al., Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab, Blood, vol.113, issue.16, pp.3809-3821, 2009.

H. E. Kohrt, A. D. Colevas, R. Houot, K. Weiskopf, M. J. Goldstein et al., Targeting CD137 enhances the efficacy of cetuximab, J Clin Invest, vol.124, issue.6, pp.2668-82, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01021651

R. M. Srivastava, S. C. Lee, A. Filho, P. A. Lord, C. A. Jie et al., Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients, Clin Cancer Res, vol.19, issue.7, pp.1858-72, 2013.

J. D. Wolchok and T. A. Chan, Cancer: Antitumour immunity gets a boost, Nature, vol.515, issue.7528, pp.496-504, 2014.

D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, issue.4, pp.252-64, 2012.

J. R. Brahmer, S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, vol.366, issue.26, pp.2455-65, 2012.

O. Hamid, C. Robert, A. Daud, F. S. Hodi, W. J. Hwu et al., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, vol.369, issue.2, pp.134-178, 2013.
DOI : 10.1056/nejmoa1305133

URL : http://europepmc.org/articles/pmc4126516?pdf=render

S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, vol.366, issue.26, pp.2443-54, 2012.

F. S. Hodi, M. Sznol, H. M. Kluger, D. F. Mcdermott, R. D. Carvajal et al., Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS936558, ONO-4538) in a phase I trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.32, issue.5s, p.9002, 2014.

Z. Topalian, G. A. Niklasson, C. G. Granqvist, and L. Osterlund, Spectroscopic study of the photofixation of SO2 on anatase TiO2 thin films and their oleophobic properties, ACS Appl Mater Interfaces, vol.4, issue.2, pp.672-681, 2012.

B. P. Harvey, R. J. Gee, A. M. Haberman, M. J. Shlomchik, and M. J. Mamula, Antigen presentation and transfer between B cells and macrophages, Eur J Immunol, vol.37, issue.7, pp.1739-51, 2007.
DOI : 10.1002/eji.200636452

E. B. Garon, A. Balmanoukian, O. Hamid, R. Hui, L. Gandhi et al., MK3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity, Clin Cancer Res, vol.20, p.20, 2014.
DOI : 10.1158/1078-0432.14aacriaslc-a20

S. N. Gettinger, F. A. Shepherd, S. J. Antonia, J. R. Brahmer, L. Q. Chow et al., First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PDL1 status, J Clinical Invest, vol.32, issue.5s, p.8024, 2014.

A. Amin, E. R. Plimack, J. R. Infante, M. S. Ernstoff, B. I. Rini et al.,

, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC), BMS-936558, vol.32, p.5010, 2014.

R. J. Motzer, B. I. Rini, D. F. Mcdermott, B. G. Redman, T. Kuzel et al., Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.32, issue.5s, p.5009, 2014.

R. S. Herbst, J. C. Soria, M. Kowanetz, G. D. Fine, O. Hamid et al., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.515, issue.7528, pp.563-570, 2014.

S. M. Ansell, A. M. Lesokhin, I. Borrello, A. Halwani, E. C. Scott et al., PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl JMed, vol.372, issue.4, pp.311-320, 2015.

T. Y. Seiwert, B. Burtness, J. Weiss, I. Gluck, J. P. Eder et al., A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.32, issue.5s, p.6011, 2014.

N. H. Segal, S. J. Antonia, J. R. Brahmer, M. Maio, A. Blake-haskins et al., Preliminary data from a multi-arm expansion study of MEDI4736, an antiPD-L1 antibody, J Clin Oncol Off J Am Soc Clin Oncol, vol.32, issue.5s, p.3002, 2014.

T. Powles, J. P. Eder, G. D. Fine, F. S. Braiteh, Y. Loriot et al., MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, vol.515, issue.7528, pp.558-62, 2014.

J. Couzin-frankel, Breakthrough of the year 2013, Cancer immunotherapy. Science, vol.342, issue.6165, pp.1432-1435, 2013.

J. L. Riley, Combination checkpoint blockade-taking melanoma immunotherapy to the next level, N Engl J Med, vol.369, issue.2, pp.187-196, 2013.

P. C. Tumeh, C. L. Harview, J. H. Yearley, I. P. Shintaku, E. J. Taylor et al., PD1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, issue.7528, pp.568-71, 2014.

J. Galon, H. K. Angell, D. Bedognetti, and F. M. Marincola, The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures, Immunity, vol.39, issue.1, pp.11-26, 2013.

S. Ogino, J. Galon, C. S. Fuchs, and G. Dranoff, Cancer immunology-analysis of host and tumor factors for personalized medicine, Nat Rev Clin Oncol, vol.8, issue.12, pp.711-720, 2011.

G. Bindea, B. Mlecnik, M. Tosolini, A. Kirilovsky, M. Waldner et al., Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer, Immunity, vol.39, issue.4, pp.782-95, 2013.

E. C. Stack, C. Wang, K. A. Roman, and C. C. Hoyt, Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis, Methods, vol.70, issue.1, pp.46-58, 2014.

D. Bedognetti, E. Wang, M. R. Sertoli, and F. M. Marincola, Gene-expression profiling in vaccine therapy and immunotherapy for cancer, Expert Rev Vaccines, vol.9, issue.6, pp.555-65, 2010.

T. F. Gajewski, M. Fuertes, R. Spaapen, Y. Zheng, and J. Kline, Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment, Curr Opin Immunol, vol.23, issue.2, pp.286-92, 2011.

H. Robins, Immunosequencing: applications of immune repertoire deep sequencing, Curr Opin Immunol, vol.25, issue.5, pp.646-52, 2013.

J. Delyon, C. Mateus, D. Lefeuvre, E. Lanoy, L. Zitvogel et al., Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival, Ann Oncol, vol.24, issue.6, pp.1697-703, 2013.

J. Naidoo, D. B. Page, and J. D. Wolchok, Immune modulation for cancer therapy, Br J Cancer, vol.111, issue.12, pp.2214-2223, 2014.

G. Y. Ku, J. Yuan, D. B. Page, S. E. Schroeder, K. S. Panageas et al., Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival, Cancer, vol.116, issue.7, pp.1767-75, 2010.

M. A. Postow, J. Yuan, K. S. Panageas, K. Bogatch, M. K. Callahan et al., Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3 mg/kg), J Clin Oncol Off J Am Soc Clin Oncol, vol.30, p.8575, 2012.

A. Marabelle, H. Kohrt, C. Caux, and R. Levy, Intratumoral immunization: a new paradigm for cancer therapy, Clin Cancer Res, vol.20, p.1747, 2014.

R. C. Bast, B. Zbar, T. Borsos, and H. J. Rapp, BCG and cancer, N Engl J Med, vol.290, issue.26, pp.1458-69, 1974.

M. Van-seters, M. Van-beurden, F. J. Kate, I. Beckmann, P. C. Ewing et al., Treatment of vulvar intraepithelial neoplasia with topical imiquimod, N Engl J Med, vol.358, issue.14, pp.1465-73, 2008.

J. D. Brody, W. Z. Ai, D. K. Czerwinski, J. A. Torchia, M. Levy et al., In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, issue.28, pp.4324-4356, 2010.

Y. H. Kim, D. Gratzinger, C. Harrison, J. D. Brody, D. K. Czerwinski et al., In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study, Blood, vol.119, issue.2, pp.355-63, 2012.

J. Heo, T. Reid, L. Ruo, C. J. Breitbach, S. Rose et al., Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer, Nature Med, vol.19, issue.3, pp.329-365, 2013.

R. Andtbacka, F. A. Collichio, T. Amatruda, N. N. Senzer, J. Chesney et al., OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GMCSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma, J Clin Oncol, vol.31, p.9008, 2013.

M. L. Disis, Y. Dang, A. L. Coveler, E. Marzbani, Z. C. Kou et al., HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers, Cancer Immunol Immunother, vol.63, issue.2, pp.101-110, 2014.

J. L. Gulley, P. M. Arlen, R. A. Madan, K. Y. Tsang, M. P. Pazdur et al., Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer, Cancer Immunol Immunother, vol.59, issue.5, pp.663-74, 2010.

J. Yuan, S. Gnjatic, H. Li, S. Powel, H. F. Gallardo et al., CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit, Proc Natl Acad Sci U S A, vol.105, issue.51, pp.20410-20415, 2008.

M. Slota, J. B. Lim, Y. Dang, and M. L. Disis, ELISpot for measuring human immune responses to vaccines, Expert Rev Vaccines, vol.10, issue.3, pp.299-306, 2011.

Z. Moodie, L. Price, S. Janetzki, and C. M. Britten, Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories, Methods Molecular Biol, vol.792, pp.185-96, 2012.

A. Mori, S. Deola, L. Xumerle, V. Mijatovic, G. Malerba et al., Next generation sequencing: new tools in immunology and hematology, Blood Res, vol.48, issue.4, pp.242-251, 2013.

L. H. Butterfield, A. Ribas, V. B. Dissette, S. N. Amarnani, H. T. Vu et al., Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma, Clin Cancer Res, vol.9, issue.3, pp.998-1008, 2003.

H. E. Kohrt, N. Nouri, K. Nowels, D. Johnson, S. Holmes et al., Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer, PLoS Med, vol.2, issue.9, p.284, 2005.

A. Y. Chang, N. Bhattacharya, J. Mu, A. F. Setiadi, V. Carcamo-cavazos et al., Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients, J Transl Med, vol.11, p.242, 2013.

V. Rubio, T. B. Stuge, N. Singh, M. R. Betts, J. S. Weber et al., Ex vivo identification, isolation and analysis of tumor-cytolytic T cells, Nature Med, vol.9, issue.11, pp.1377-82, 2003.

T. B. Stuge, S. P. Holmes, S. Saharan, A. Tuettenberg, M. Roederer et al., Diversity and recognition efficiency of T cell responses to cancer, PLoS Med, vol.1, issue.2, p.28, 2004.

H. E. Kohrt, C. T. Shu, T. B. Stuge, S. P. Holmes, J. Weber et al., Rapid assessment of recognition efficiency and functional capacity of antigen-specific T-cell responses, J Immunother, vol.28, issue.4, pp.297-305, 1997.

R. O. Emerson, A. M. Sherwood, M. J. Rieder, J. Guenthoer, D. W. Williamson et al., High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer, J Pathol, vol.231, issue.4, pp.433-473, 2013.

M. Gerlinger, S. A. Quezada, K. S. Peggs, A. J. Furness, R. Fisher et al., Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas, J Pathol, vol.231, issue.4, pp.424-456, 2013.

D. L. Lamm, B. A. Blumenstein, E. D. Crawford, J. E. Montie, P. Scardino et al., A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder, N Engl J Med, vol.325, issue.17, pp.1205-1214, 1991.

E. Vacchelli, A. Eggermont, C. Sautes-fridman, J. Galon, L. Zitvogel et al., Trial watch: Oncolytic viruses for cancer therapy, Oncoimmunol, vol.2, issue.6, p.24612, 2013.

W. F. Goins, S. Huang, J. B. Cohen, and J. C. Glorioso, Engineering HSV-1 vectors for gene therapy, Methods Molecular Biol, 2014.

H. T. Maecker, J. Moon, S. Bhatia, S. A. Ghanekar, V. C. Maino et al., Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT, BMC Immunol, vol.6, p.17, 2005.

M. Kalos, An integrative paradigm to impart quality to correlative science, J Transl Med, vol.8, p.26, 2010.

H. T. Maecker, J. P. Mccoy, and R. Nussenblatt, Standardizing immunophenotyping for the Human Immunology Project, Nat Rev Immunol, vol.12, issue.3, pp.191-200, 2012.

G. C. Keustermans, S. B. Hoeks, J. M. Meerding, B. J. Prakken, and W. De-jager, Cytokine assays: an assessment of the preparation and treatment of blood and tissue samples, Methods, vol.61, issue.1, pp.10-17, 2013.

S. H. Van-der-burg, M. Kalos, C. Gouttefangeas, S. Janetzki, C. Ottensmeier et al., Harmonization of immune biomarker assays for clinical studies, Sci Transl Med, vol.3, issue.108, pp.108-152, 2011.

H. T. Maecker, J. P. Mccoy, A. M. Elliott, J. Gaigalas, A. Wang et al., A model for harmonizing flow cytometry in clinical trials, Nature Immunol, vol.11, issue.11, pp.975-983, 2010.

C. F. Taylor, D. Field, S. A. Sansone, J. Aerts, R. Apweiler et al., Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project, Nature Biotechnol, vol.26, issue.8, pp.889-96, 2008.